Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
van Wijck-Stam-Caspers Foundation
Stichting de Drie Lichten
Short Term Scientific Mission of the PARENCHIMA COST action
Horizon 2020 (115974)
- License Information
-
More Information
Article History
Received: 7 February 2024
Revised: 7 December 2024
Accepted: 14 January 2025
First Online: 15 February 2025
Declarations
:
: The authors declare that they do not have a conflict of interest. S. Sourbron, K. Sharma and B. Alhummiany are supported by the BEAt-DKD project. The BEAt-DKD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA. A. de Boer received financial support from the Dutch van Wijck-Stam-Caspers foundation, the Drie Lichten foundation (Dutch non-profit foundations) and a Short Term Scientific Mission of the PARENCHIMA COST action (CA16103).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
